Exelixis [EXEL] vs Regeneron [REGN] Detailed Stock Comparison
Exelixis
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Exelixis wins in 10 metrics, Regeneron wins in 9 metrics, with 0 ties. Exelixis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Exelixis | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 18.04 | 14.95 | Regeneron |
| Price-to-Book Ratio | 4.98 | 2.06 | Regeneron |
| Debt-to-Equity Ratio | 8.84 | 9.04 | Exelixis |
| PEG Ratio | -1.41 | 13.09 | Exelixis |
| EV/EBITDA | 12.14 | 12.21 | Exelixis |
| Profit Margin (TTM) | 27.01% | 31.37% | Regeneron |
| Operating Margin (TTM) | 37.58% | 29.64% | Exelixis |
| EBITDA Margin (TTM) | 37.58% | 29.64% | Exelixis |
| Return on Equity | 29.00% | 15.34% | Exelixis |
| Return on Assets (TTM) | 17.24% | 6.66% | Exelixis |
| Free Cash Flow (TTM) | $633.79M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | 49.57% | -50.12% | Exelixis |
| Price-to-Sales Ratio (TTM) | 4.53 | 4.42 | Regeneron |
| Enterprise Value | $9.49B | $54.52B | Regeneron |
| EV/Revenue Ratio | 4.26 | 3.84 | Regeneron |
| Gross Profit Margin (TTM) | 96.57% | 85.58% | Exelixis |
| Revenue per Share (TTM) | $8 | $133 | Regeneron |
| Earnings per Share (Diluted) | $2.08 | $39.68 | Regeneron |
| Beta (Stock Volatility) | 0.29 | 0.33 | Exelixis |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Exelixis vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Exelixis | -0.18% | 0.62% | -12.54% | -11.46% | 5.05% | 14.05% |
| Regeneron | 1.21% | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Exelixis | 49.57% | 112.34% | 78.96% | 539.83% | 1,087.42% | 410.69% |
| Regeneron | -50.12% | 0.33% | -0.74% | 11.45% | 2,525.81% | 7,886.11% |
Performance & Financial Health Analysis: Exelixis vs Regeneron
| Metric | EXEL | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $10.10B | $62.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,489,940 | 859,422 |
| 90 Day Avg. Volume | 3,312,780 | 933,271 |
| Last Close | $38.64 | $598.16 |
| 52 Week Range | $25.12 - $49.62 | $476.49 - $1,211.20 |
| % from 52W High | -22.13% | -50.61% |
| All-Time High | $50.50 (Jul 10, 2000) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -23.49% | -50.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.11% | 0.04% |
| Quarterly Earnings Growth | -0.18% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.27% | 0.31% |
| Operating Margin (TTM) | 0.38% | 0.30% |
| Return on Equity (TTM) | 0.29% | 0.15% |
| Debt to Equity (MRQ) | 8.84 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.53 | $287.55 |
| Cash per Share (MRQ) | $2.94 | $72.04 |
| Operating Cash Flow (TTM) | $772.03M | $4.74B |
| Levered Free Cash Flow (TTM) | $637.96M | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Exelixis vs Regeneron
| Metric | EXEL | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 18.04 | 14.95 |
| Forward P/E | 22.07 | 13.09 |
| PEG Ratio | -1.41 | 13.09 |
| Price to Sales (TTM) | 4.53 | 4.42 |
| Price to Book (MRQ) | 4.98 | 2.06 |
| Market Capitalization | ||
| Market Capitalization | $10.10B | $62.88B |
| Enterprise Value | $9.49B | $54.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.26 | 3.84 |
| Enterprise to EBITDA | 12.14 | 12.21 |
| Risk & Other Metrics | ||
| Beta | 0.29 | 0.33 |
| Book Value per Share (MRQ) | $7.53 | $287.55 |
Financial Statements Comparison: Exelixis vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EXEL | REGN |
|---|---|---|
| Revenue/Sales | $555.45M | $3.03B |
| Cost of Goods Sold | $19.17M | $464.30M |
| Gross Profit | $536.28M | $2.56B |
| Research & Development | $212.23M | $1.34B |
| Operating Income (EBIT) | $186.86M | $591.70M |
| EBITDA | $194.20M | $900.90M |
| Pre-Tax Income | $205.69M | $905.00M |
| Income Tax | $46.07M | $96.30M |
| Net Income (Profit) | $159.62M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EXEL | REGN |
|---|---|---|
| Cash & Equivalents | $183.75M | $3.09B |
| Total Current Assets | $1.40B | $17.57B |
| Total Current Liabilities | $399.10M | $3.57B |
| Long-Term Debt | $187.13M | $2.70B |
| Total Shareholders Equity | $2.13B | $29.39B |
| Retained Earnings | $-163.29M | $32.38B |
| Property, Plant & Equipment | $338.58M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EXEL | REGN |
|---|---|---|
| Operating Cash Flow | $186.51M | $1.36B |
| Capital Expenditures | $-2.95M | N/A |
| Free Cash Flow | $188.99M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-283.93M | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | EXEL | REGN |
|---|---|---|
| Shares Short | 17.37M | 2.29M |
| Short Ratio | 4.76 | 2.55 |
| Short % of Float | 0.09% | 0.02% |
| Average Daily Volume (10 Day) | 2,489,940 | 859,422 |
| Average Daily Volume (90 Day) | 3,312,780 | 933,271 |
| Shares Outstanding | 281.73M | 109.62M |
| Float Shares | 231.84M | 97.89M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 0.97% | 0.91% |
Dividend Analysis & Yield Comparison: Exelixis vs Regeneron
| Metric | EXEL | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |